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RNA interference (RNAi) can still be regarded as a re-
cently discovered phenomenon, but it has already made 
its way as a widely used method in molecular biology. 
In 1998, Andrew Fire and Craig Mello were the first to 
describe  the  mechanism  of  RNAi  in  the  nematode  C. 
elegans (Fire et al, 1998). Long double-stranded RNA 
molecules  were  found  to  mediate  posttranscriptional 
silencing of genes with a homologous sequence. How-
ever,  such long  double-stranded  RNAs were  found to 
induce the interferon response in mammalian cells, and 
it  took  another  few  years  before  Thomas  Tuschl  and 
colleagues found a way to use this method in mammal-
ian  cells  by  discovering  that  small  interfering  RNAs 
(siRNAs) – being 21 nucleotides in length – could be 
employed to induce RNAi without activating the inter-
feron  response  (Elbashir  et  al,  2001).  This  landmark 
publication has been cited nearly 2000 times according 
to the ISI Web of Knowledge (August 2005) and initi-
ated a boost of studies employing this novel, powerful 
technique.  In  fact,  the  annual  number  of  papers  on 
RNAi has the highest rate of growth in the biotech lit-
erature (Lawrence, 2005). Furthermore, this newly dis-
covered universe of small RNA molecules was elected 
to  be  the  breakthrough  of  the  year  in  2002  (Couzin, 
2002) and since it has been in the Top 10 in the preced-
ing  and  succeeding  years.  Many  scientists  consider 
RNAi to be the most important revolution in molecular 
biology since the discovery of polymerase chain reac-
tion  (PCR).  It  is  anticipated  that,  just  like  PCR,  the 
method of RNAi is to become a standard procedure in 
almost any life science laboratory around the world. 
 
RNAi  is now  being  used at  various  levels: Academic 
researchers  are  usually  interested  in  the  function  of  a 
single gene and try to understand its function by study-
ing a loss-of-function phenotype. In contrast, big cen-
tres and companies have set up libraries for large scale 
screens employing thousands of siRNAs or short hair-
pin  RNA  (shRNA)  encoding  vectors  to  identify  new 
factors  involved  in  certain  pathways.  Pharmaceutical 
companies make use of RNAi as a rapid approach for 
target  validation  before  screening  large  libraries  for 
small  molecular  drugs.  Medical  researchers  have  new 
opportunities  to  study  disease  models  in  vivo  without 
the  need  to  generate  expensive  and  time  consuming 
knock-out animals. It is mainly biotech companies that 
try to develop siRNAs into a new class of therapeutics. 
For a long-term perspective the vision has been brought 
up that RNAi might drastically accelerate the process of 
drug  development.  New  targets  can  be  identified  by 
genome-wide screens with siRNA libraries; the siRNA 
can immediately be used for target validation and only 
minor modifications of the same siRNA according to a 
standard pattern will be necessary to use it in clinical 
settings.  
 
Only just over three years after the initial demonstration 
that siRNAs can be used to silence genes in mammalian 
cells, the first clinical trials based on RNAi were initi-
ated  in  late  2004.  Acuity  Pharmaceutical  and  Sirna 
Therapeutics commenced studies to treat patients with 
age-related  macular  degeneration  (AMD)  with  in-
travitreally  injected  siRNAs  targeting  VEGF  and  its 
receptor, respectively. First data from these trials dem-
onstrate  that  the  drug  is  safe  and  well  tolerated,  and 
even some promising indications on the visual acuity of 
the  patients  have  been  reported  (Whelan,  2005),  al-
though the effectiveness of a new drug is not in the fo-
cus of a phase I trial. 
 
Despite this enthusiasm about the new tools available 
now, some problems will have to be dealt with openly. 
Off-target  effects  and  the  induction  of  the  interferon 
response even by the short double-stranded RNA mole-
cules have intensively been discussed in the scientific 
community.  These  caveats  make  clear  that  data  ob-
tained in RNAi experiments have to be interpreted with 
great  care  and  that  proper  controls  are  indispensable. 
The future will show whether the unspecific effects of 
RNAi will prohibit the extended use of this method for 
systemic application of siRNAs in humans. One must, 
however, keep in mind that almost every drug has its 
unwanted  side-effects  and  we  will  have  to  find  out 
whether the benefits of an RNAi treatment outweigh its  
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adverse effects. In some cases, e.g. treatment of  viral 
infections,  a  moderate  induction  of  the  interferon  re-
sponse might even be a beneficial aid for the specific 
treatment by siRNAs. 
 
The  field  of  RNAi  is  highly  dynamic  with  dozens  of 
publications  added  to  the  database  every  week.  Re-
searchers in the field do not only profit from the great 
interest in RNAi, but also have to cope with hard com-
petition. We, therefore, see a need for a journal special-
ized on this topic. Authors will profit from rapid han-
dling  of  their  manuscripts  and  open  access  to  all  ac-
cepted  papers  which  guarantees  wide  recognition  of 
their  work.  The  Journal  of  RNAi  and  Gene  Silencing 
will not only deal with RNAi, but also welcomes stud-
ies with traditional antisense and ribozyme applications. 
These techniques are still extremely valuable as a com-
plementary approach and researchers in the RNAi field 
will definitively benefit from lessens learned with an-
tisense  oligonucleotides  and  ribozymes  in  the  last  25 
years.  We  are  therefore  excited  to  receive  numerous 
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